These results emphasize the relevance for future studies to potentially deploy TIL clusters as a biomarker for BRAF V600E/K mutated MM, where either immunotherapy or targeted therapies may be considered as treatment regimens. The gene discussed is BRAF; the disease is Miyoshi myopathy.